EUVIMEDOpdag EUVIMED
Open access

Outcomes After 4‐Week Course of Sofosbuvir/Velpatasvir Therapy in Hepatitis C Seronegative Recipients of Kidneys From Hepatitis C Viremic Deceased Donors

Basheer Ahamad Kummangal iD, Madelaine Hack iD, Sri Abirami Selvam iD, Christopher Connelly iD, Justin Smith iD, Jay Pandav iD, Angelo de Mattos, Long Do, Aaron Ziolko, Domenica McKenna, Shehzad Rehman iD

Clinical Transplantation · 2026

DOI: 10.1111/ctr.70629 ↗

At a glance

Journal article in Clinical Transplantation, 2026. Written by Basheer Ahamad Kummangal and 10 co-authors. Institution: Division of Nephrology and Hypertension, VA Portland Health Care System, Portland, Oregon, USA. Major MEDLINE topics: Sofosbuvir, Kidney Transplantation, Heterocyclic Compounds, 4 or More Rings, Carbamates. 27 references. The full text is freely available in PubMed Central.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Kidney transplantation from hepatitis C virus (HCV) viremic deceased donors into HCV seronegative recipients helps to expand the donor pool. The optimal duration of direct acting antiviral (DAA) prophylaxis remains undefined.

Methods

We performed a retrospective review of all HCV seronegative adults who received a kidney transplant from an HCV nucleic acid test (NAT) positive deceased donor at the VA Portland Medical Center between September 2017 and March 2025 and were treated with sofosbuvir/velpatasvir (SOF/VEL) prophylaxis for 28 days postoperatively. The primary outcome was sustained virologic response 12 weeks after completion of prophylaxis (initial SVR12). Secondary outcomes at 1 year included HCV treatment success rate, biopsy proven acute rejection (BPAR), delayed graft function (DGF), eGFR, liver enzyme abnormalities, CMV and BK viremia, adverse events, and all‐cause mortality.

Results

Fifty patients were included. The mean age was 62.8 ± 10.9 years, 92% were male, mean EPTS was 63.7 ± 29.2 and mean KDPI was 59.8 ± 19.6. Initial SVR12 after completion of prophylaxis was achieved in 46/50 (92%), out of which 2 patients had their SOF/VEL prophylaxis extended to 12 weeks because of transient viremia. Four patients (8%) failed prophylaxis and required HCV treatment with all achieving SVR (100% overall SVR). DGF occurred in 16%, BPAR in 12%, CMV viremia in 18%, and BK viremia in 16%. Mean 1‐year eGFR was 57.7 ± 18.7 mL/min/1.73 m 2 . No DAA attributable adverse events were recorded. One‐year all‐cause mortality was 2% (1/50) and was unrelated to HCV or DAA. Older age (72.3 ± 4.0 vs. 62.0 ± 11.0 years, p = 0.030) and higher Estimated Post Transplant Survival (EPTS) scores (86.5 ± 19.1 vs. 61.8 ± 29.3, p = 0.041) correlated significantly with prophylaxis failure.

Conclusion

A 4‐week SOF/VEL prophylaxis regimen coupled with HCV RNA surveillance and treatment appears to be safe and effective in a Veterans Affairs population.

Subjects

MeSH terms (MEDLINE)

SofosbuvirKidney TransplantationHeterocyclic Compounds, 4 or More RingsCarbamatesTissue DonorsHepatitis CGraft RejectionViremiaPostoperative ComplicationsHumansMaleFemaleMiddle AgedRetrospective StudiesAntiviral AgentsHepacivirusFollow-Up StudiesGraft SurvivalPrognosisBenzimidazolesRisk FactorsAgedDrug CombinationsBenzopyrans

Author keywords

deceased donordirect‐acting antiviralhepatitis C viruskidney transplantationorgan utilizationsofosbuvir/velpatasvir

Substances

SofosbuvirAntiviral AgentsHeterocyclic Compounds, 4 or More RingsCarbamatesBenzimidazolesvelpatasvirsofosbuvir-velpatasvir drug combinationDrug CombinationsBenzopyrans

Authors and institutions

  • Division of Nephrology and Hypertension, VA Portland Health Care System, Portland, Oregon, USA.
  • Division of Nephrology and Hypertension, Oregon Health & Science University, Portland, Oregon, USA.
  • Division of Abdominal Organ Transplantation, VA Portland Health Care System, Portland, Oregon, USA.
  • Division of Abdominal Organ Transplantation, Oregon Health & Science University, Portland, Oregon, USA.
  • Department of Pharmacy Services, VA Portland Health Care System, Portland, Oregon, USA.

ORCID profiles: Basheer Ahamad Kummangal, Madelaine Hack, Sri Abirami Selvam, Christopher Connelly, Justin Smith, Jay Pandav, Shehzad Rehman

Cite

APA

Kummangal, B. A., Hack, M., Selvam, S. A., Connelly, C., Smith, J., Pandav, J., Mattos, A., Do, L., Ziolko, A., McKenna, D., & Rehman, S. (2026). Outcomes After 4‐Week Course of Sofosbuvir/Velpatasvir Therapy in Hepatitis C Seronegative Recipients of Kidneys From Hepatitis C Viremic Deceased Donors. Clinical Transplantation. https://doi.org/10.1111/ctr.70629

Vancouver

Kummangal BA, Hack M, Selvam SA, Connelly C, Smith J, Pandav J, et al. Outcomes After 4‐Week Course of Sofosbuvir/Velpatasvir Therapy in Hepatitis C Seronegative Recipients of Kidneys From Hepatitis C Viremic Deceased Donors. Clinical Transplantation. 2026. doi:10.1111/ctr.70629

BibTeX
@article{Kummangal2026,
  author = {Kummangal, Basheer Ahamad and Hack, Madelaine and Selvam, Sri Abirami and Connelly, Christopher and Smith, Justin and Pandav, Jay and Mattos, Angelo de and Do, Long and Ziolko, Aaron and McKenna, Domenica and Rehman, Shehzad},
  title = {Outcomes After 4‐Week Course of Sofosbuvir/Velpatasvir Therapy in Hepatitis C Seronegative Recipients of Kidneys From Hepatitis C Viremic Deceased Donors},
  journal = {Clinical Transplantation},
  year = {2026},
  doi = {10.1111/ctr.70629}
}
Start for free →